Hemlibra in Mild Hemophilia A

• Status: Recruiting
• Trial end date: 2024-02-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a single arm, phase 4, prospective, open-label, United States single-center study to determine the hemostatic characteristics of Hemlibra (emicizumab) as measured by coagulation laboratory parameters in the mild hemophilia A male patient population with endogenous altered FVIII (baseline FVIII activity of >5% to 30%). The safety and hemostatic efficacy of Hemlibra (emicizumab) in this patient population will be investigated. Secondary outcomes will assess changes in joint health and quality of life in treated patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indiana Hemophilia &Thrombosis Center, Inc.
• Collaborator: Genentech, Inc.

Criteria

Inclusion Criteria:

• Signed informed consent form from the subject, parent or guardian

• Male sex

• Diagnosis of mild congenital hemophilia A (baseline FVIII level of >5% to 30%) without a current FVIII inhibitor or a history of FVIII inhibitor

• Any number of FVIII exposure days, including PUPs

• BMI <30

• Age ≥5 years to ≤45 years

• Medical documentation of bleeding events, outcomes and hemostatic product usage for 12 months prior to study enrollment

• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, including the health-related questionnaires, activity tracking, and bleed diaries, using systems provided during the study

• Willingness to undergo a Stimate/DDAVP challenge (only if the subject reports no adverse event associated with prior Stimate [DDAVP/desmopressin acetate] use); Stimate/DDAVP challenge will not be performed if the patient has a documented history of lack of response as defined by an increase of FVIII < 2 times baseline level

• Adequate hepatic function, defined as total bilirubin ≤1.5 × age-adapted upper limit of normal (ULN) (excluding Gilbert's syndrome) and both AST and ALT ≤3 × age-adapted ULN at the time of screening, and no clinical signs or known laboratory/radiographic evidence consistent with cirrhosis

• Adequate hematologic function, defined as a platelet count ≥100,000/μL and a PT≤1.5 times the ULN at the time of screening

• Adequate renal function, defined as serum creatinine ≤2.5 × age-adapted ULN and creatinine clearance ≥30 mL/min by Cockcroft-Gault formula

Exclusion Criteria:

• Inherited or acquired bleeding disorder other than mild congenital hemophilia A (baseline FVIII level of >5% to 30%)

• Any bleeding disorder other than or in addition to mild hemophilia A

• Current or prior inhibitor to FVIII (any titer)

• Female sex

• History of CVD, risk of CVD by the ASCVD risk estimator (defined as a subject having >20% risk of a cardiovascular event within the next 10 years if the subject is ≥20 years of age) and/or a history of ischemic heart disease [ICD codes 120-125]

• High risk for TMA (eg, have a previous medical or family history of TMA), in the Study Investigator's judgment

• History of illicit drug or alcohol abuse by report or in the Study Investigator's judgment

• Previous (within the last 12 months) or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease

• Other conditions (eg, certain autoimmune diseases) that may currently increase the risk of bleeding or thrombosis

• History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the Hemlibra (emicizumab) injection

• Known HIV infection with CD4 counts <200 cells/μL. HIV infection with CD4 counts ≥200 cells/μL permitted

• Use of systemic immunomodulators (eg, interferon) at enrollment or planned use during the study, with the exception of anti-retroviral therapy

• Concomitant disease, condition, significant abnormality on screening evaluations or laboratory tests, or treatment that could interfere with the conduct of the study, or that would, in the opinion of the Study Investigator, pose an additional unacceptable risk in administering study drug to the patient

• Receipt of any of the following:

• Hemlibra (emicizumab) in a prior investigational study

• An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration

• A non-hemophilia-related investigational drug within last 30 days or 5 half-lives, whichever is shorter

• Any other investigational drug currently being administered or planned to be administered

• Inability to comply with the study protocol in the opinion of the Study Investigator